Cancer Immunotherapy 2006

An International Symposium Sponsored by the Cancer Research Institute.

Abstracts:

• James P. Allison. Checkpoint Blockade in Tumor Immunotherapy. Memorial Sloan-Kettering Cancer Center, New York, NY.
• Robert D. Schrieber¹, Catherine Koebel¹, Gavin Dunn¹, William Vermi¹, Mark Smyth², Lloyd Old³. Deciphering the Compex Interaction of the Immune System with Developing Tumors.
  ¹ Washington University School of Medicine, St. Louis, MO.
  ² Peter MacCallum Cancer Institute, Victoria, Australia.
  ³ Ludwig Institute for Cancer Research, New York, NY.
• Michael Karin. Connecting Inflammation and Cancer Through the IKK-NF-kB Nexus. University of California, San Diego, La Jolla, CA.
• Giorgio Trinchieri. Toll-Like Receptors, Cancer, and Inflammation. Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD.
• Adrian Hayday¹, Jessica Strid¹, David Vermijlen¹, Michael Girardi². NKG2D, Unconventional T Cells, and the Regulation of Carcinogenesis.
  ¹ King's College School of Medicine at Guy's Hospital,London, United Kingdom.
  ² Yale University School of Medicine, New Haven, CT.
• Kenneth L. Rock. Immune Surveillance of Tumors and Immunodominance of Responses. University of Massachusetts Medical School, Worcester, MA.
• Zheng Cui. A Remarkable Mouse. Wake Forest University School of Medicine, Winston Salem, NC.
• Mark Davis, Michelle Krogsgaard, Daniel Chen, Morgan Huse, Qi-Jing Li, Johannes Huppa, Yoav Soen, Jeffery S. Weber, Patrick O. Brown, Chang-Zheng Chen. T-Cell Recognition in Health and Disease: The Role of Self-Peptides and High-Throughput Analysis of the Response to a Cancer Vaccine. Stanford University School of Medicine, Stanford, CA; University of Southern California, Los Angeles, CA
• Hua Yu. Role of Stat3 in Mediating the Crosstalk Between Tumor and Immune Cells. City of Hope National Medical Center, Duarte, CA.
• Wolfgang Weninger. Visualizing Intratumoral Immune Responses. The Wistar Institute, Philadelphia, PA.
• Giuseppe Pantaleo. Functional Signatures of Protective Antiviral T-Cell Immunity: A Guide to the Development of Vaccine Strategies. University of Lausanne, Lausanne, Switzerland.
• Ricardo T. Gazzinelli. Protozoan Associated Molecular Patterns and Toll-Like Receptors: New Microbial Adjuvants for Immunological Intervention? Federal University of Minas Gerais, Minas, Brazil; University of Massachusetts Medical School, Worcester, MA.
• Jonathan Cebon¹, Craig Gedye¹, Ian Davis¹, Juliet Quirk¹, Weisan Chen¹, Andrew Simpson², Otavia Caballero², Lloyd J. Old². Vaccinating Against Cancer's Achilles' Heel.
  ¹ Ludwig Institute for Cancer Research, Melbourne, Australia
  ² Ludwig Institute for Cancer Research, New York, NY
• Danila Valmori. Cross-Priming and Cancer Vaccines. Columbia University, College of Physicians & Surgeons,New York, NY.
• Glenn Dranoff. Mechanisms of Protective Tumor Immunity. Dana-Farber Cancer Institute, Boston, MA.
• Elizabeth M. Jaffee. Genes, Vaccines, and Immune Checkpoints: An All Out Attack on Pancreatic Cancer. The Signey Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD.
• Wolf H. Fridman¹², J. Galon¹, F. Pagès², A. Berger². The Immunological Tumor Microenvironment Predicts Clinical Outcome in Human Colorectal Cancer.
  ¹ INSERM U255
  ² Hopital European Georges Pompidou, Université Paris, Paris, France
• Carl June, Michael Milone, Carmine Carpenito, Jonathon Fish, Stephan Grupp. Lentiviral Engineered T Cells for Tumor Therapy: Are We There Yet? Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
• Ronald Levy. Therapeutic Vaccination for Lymphoid Malignancy. Stanford University School of Medicine, Stanford, CA.
• Cornelis J. Melief, MJP Welters, MJG Löwik, APG Vloon, JW Drijfhout, ARPM Valentijn, AR Wafelman, GJ Fleuren, R Offringa, SH van der Burg, GG Kenter. Long Peptide Vaccine-Induced Migration of HPV16-Specific Type 1 and 2 T Cells Into the Lesions of VIN III Patients Associated With Complete Clinical Responses. Leiden University Medical Center, Leiden, The Netherlands.
• Eli Gilboa¹, Smita Nair², David Boczkowski². Targeting Immune Evasion in Cancer Immunotherapy.
  ¹ University of Miami, Miami, FL
  ² Duke University Medical Center, Durham, NC
• Cassian Yee. Adoptive T-Cell Therapy. Fred Hutchinson Cancer Research Center, Seattle, WA.
• Nicholas P. Restifo. Adoptive Immunotherapy for Cancer: Building on Success. National Cancer Institute, NIH, Bethesda, MD.